Opportunities and constraints in schistosomiasis vaccine development: infection characteristics and industry realities.
The notes provided in this article relate to two components of the development of vaccines against schistosomiasis: (1) The characteristics of schistosome infections (eg. features of the schistosome life cycle), and the parasite itself, that have implications for vaccination strategies; (2) The characteristics of the biopharmaceutical industry that have implications for product development. As will be seen, these two topic areas are not vastly disparate.
Mitchell
G F
GF
R&D Division, CSL Limited, Parkville, Victoria, Australia.
D000818:Animals; D004345:Drug Industry / Q000639:trends*; D005260:Female; D006790:Host-Parasite Interactions; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D012547:Schistosoma / Q000502:physiology; D012552:Schistosomiasis / Q000276:immunology / Q000517:prevention & control*; D014612:Vaccines
D014612:Vaccines